Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 02, 2021 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences

REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that...
February 01, 2021 11:25 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection

The SARS-CoV-2 Rapid Antigen Test Nasal uses a nasal swab to quickly and conveniently collect specimens from people suspected of having an active infection Nasal sampling allows for collection of the...
February 01, 2021 08:32 ET | Source: BioNTech SE

Pfizer und BioNTech veröffentlichen präklinische Daten zu COVID-19-Impfstoffprogramm in Nature

New York und Mainz, Deutschland, 1. Februar 2021 — Pfizer Inc (NYSE: PFE) und BionTech SE (Nasdaq: BNTX) gaben heute die Publikation präklinischer Ergebnisse zu ihren mRNA-basierten...
February 01, 2021 08:32 ET | Source: BioNTech SE

Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature

New York, NY and Mainz, Germany, February 1, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preclinical data in non-human primate and mouse models...
February 01, 2021 05:30 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada

- Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody- First U.S. BLA filing expected this year for nasopharyngeal...
January 29, 2021 07:00 ET | Source: AC Immune SA

AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway

Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors High-affinity antibodies against extracellular components of the inflammasome pathway show...
January 28, 2021 02:17 ET | Source: Facts & Factors

Ophthalmic drugs Market Size Estimated to Surpass USD 37,700 Million By 2026, Globally: Facts & Factors

New York, NY, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Ophthalmic Drug Market By Type (Over-the-Counter Drugs and Prescription Drugs), By Drug...
January 26, 2021 07:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
January 25, 2021 01:03 ET | Source: F. Hoffmann-La Roche Ltd

Roche renews partnership with Sysmex to deliver haematology testing solutions

This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globallyThe new agreement aims to utilise the IT systems to lead to improved...
January 25, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration

Faricimab given at intervals of up to every 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks, potentially reducing the frequency of injections and...